MdxHealth (TM) : MDxHealth's new share capital amount and number of shares

  MdxHealth (TM) : MDxHealth's new share capital amount and number of shares

LIEGE, BELGIUM  - July  2, 2013  - MDxHealth  SA (NYSE  Euronext :  MDXH),  in 
conformity with article 15  of the Law  of May 2, 2007  on the publication  of 
significant shareholdings in issuers which shares are admitted to trading on a
regulated market, and further  to the capital increase  having taken place  on 
Tuesday, June  25,  2013,  MDxHealth  publishes that  its  share  capital  has 
increased from EUR 20,351,568.70 to EUR 27,321,762.02 and that its issued  and 
outstanding shares have increased from  25,513,440 to 34,251,303, through  the 
issuance of 8,737,863 new shares.

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of  patients.  The  company's  first  commercial  product,  ConfirmMDx^TM  for 
Prostate Cancer,  has been  shown  to help  distinguish  patients who  have  a 
true-negative biopsy  from those  who may  have undetected  cancer.  MDxHealth 
helps to address  a large  and growing unmet  medical need  for better  cancer 
diagnosis and treatment  information. The company  has a proprietary  platform 
and a  strong  epigenetic  product  pipeline focused  on  the  development  of 
products for prostate, brain and lung cancers. The company is based in Irvine,
California  with  a  European  headquarters   in  Liege,  Belgium.  For   more 
information visit MDxHealth's website at

For more information: Mike Sinclair
Dr. Jan Groen, CEO    Halsin Partners
MDxHealth             UK: +44 20 7318 2955
US: +1 949 812 6979   Cell: +44 7968 022075
BE: +32 4 364 20 70 

Important notice

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.